These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25839898)

  • 21. ALCAR promote adult hippocampal neurogenesis by regulating cell-survival and cell death-related signals in rat model of Parkinson's disease like-phenotypes.
    Singh S; Mishra A; Mishra SK; Shukla S
    Neurochem Int; 2017 Sep; 108():388-396. PubMed ID: 28577987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of L-Dopa and pramipexole on plasticity induced by QPS in human motor cortex.
    Enomoto H; Terao Y; Kadowaki S; Nakamura K; Moriya A; Nakatani-Enomoto S; Kobayashi S; Yoshihara A; Hanajima R; Ugawa Y
    J Neural Transm (Vienna); 2015 Sep; 122(9):1253-61. PubMed ID: 25663170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism.
    Bonito-Oliva A; Pignatelli M; Spigolon G; Yoshitake T; Seiler S; Longo F; Piccinin S; Kehr J; Mercuri NB; Nisticò R; Fisone G
    Biol Psychiatry; 2014 May; 75(9):701-10. PubMed ID: 23541633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease.
    Alzoubi KH; Mokhemer E; Abuirmeileh AN
    Behav Brain Res; 2018 Sep; 350():109-115. PubMed ID: 29758248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new dopaminergic nigro-olfactory projection.
    Höglinger GU; Alvarez-Fischer D; Arias-Carrión O; Djufri M; Windolph A; Keber U; Borta A; Ries V; Schwarting RK; Scheller D; Oertel WH
    Acta Neuropathol; 2015 Sep; 130(3):333-48. PubMed ID: 26072303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
    Santiago RM; Tonin FS; Barbiero J; Zaminelli T; Boschen SL; Andreatini R; Da Cunha C; Lima MM; Vital MA
    Neuroscience; 2015 Aug; 300():246-53. PubMed ID: 25999296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
    Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
    Loiodice S; Winlow P; Dremier S; Hanon E; Dardou D; Ouachikh O; Hafidi A; da Costa AN; Durif F
    Psychopharmacology (Berl); 2017 Jan; 234(1):15-27. PubMed ID: 27614895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson's disease rat.
    Yang J; Song S; Li J; Liang T
    Pathol Res Pract; 2014 Jun; 210(6):357-62. PubMed ID: 24642369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
    Metz GA; Farr T; Ballermann M; Whishaw IQ
    Eur J Neurosci; 2001 Jul; 14(1):27-37. PubMed ID: 11488946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.